Gilead Sciences Inc (GILD)

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
$2.48 (-2.64%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0

About

Business overview of Gilead Sciences Inc (GILD)
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).

Key Insights

Critical company metrics and information

  • Share Price

    $91.44

  • Market Cap

    $113.96 Billion

  • Total Outstanding Shares

    1.25 Billion Shares

  • Total Employees

    18,000

  • Dividend

    $0.77 Per Share Quarterly

  • IPO Date

    January 22, 1992

  • SIC Description

    Biological Products, (no Disgnostic Substances)

  • Homepage

    https://www.gilead.com

Historical Stock Splits

If you bought 1 share of GILD before September 7, 2004, you'd have 8 shares today.
Execution DateSplit Amount
January 28, 20132-for-1
June 25, 20072-for-1
September 7, 20042-for-1

Cash Flow Statement

October 1, 2023 to September 30, 2024
MetricValue
Net Cash Flow From Investing Activities$-3.95 Billion
Net Cash Flow From Financing Activities$-6.79 Billion
Exchange Gains/Losses$52.00 Million
Net Cash Flow From Operating Activities, Continuing$10.02 Billion
Net Cash Flow$-669.00 Million
Net Cash Flow, Continuing$-721.00 Million
Net Cash Flow From Financing Activities, Continuing$-6.79 Billion
Net Cash Flow From Investing Activities, Continuing$-3.95 Billion
Net Cash Flow From Operating Activities$10.02 Billion

Income Statement

October 1, 2023 to September 30, 2024
MetricValue
Operating Income/Loss$822.00 Million
Diluted Earnings Per Share$0.09
Revenues$28.30 Billion
Net Income/Loss Attributable To Parent$126.00 Million
Gross Profit$21.54 Billion
Cost Of Revenue$6.76 Billion
Net Income/Loss$114.00 Million
Net Income/Loss Attributable To Noncontrolling Interest$-12.00 Million
Selling, General, and Administrative Expenses$5.79 Billion
Costs And Expenses$27.48 Billion
Basic Average Shares$1.25 Billion
Preferred Stock Dividends And Other Adjustments$0.00
Income/Loss From Continuing Operations After Tax$113.00 Million
Income Tax Expense/Benefit$63.00 Million
Nonoperating Income/Loss$334.00 Million
Net Income/Loss Available To Common Stockholders, Basic$126.00 Million
Basic Earnings Per Share$0.11
Benefits Costs and Expenses$28.12 Billion
Operating Expenses$20.72 Billion
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic$0.00
Other Operating Expenses$14.93 Billion
Income/Loss From Continuing Operations Before Tax$176.00 Million
Diluted Average Shares$1.25 Billion
Income Tax Expense/Benefit, Deferred$-1.83 Billion

Balance Sheet

October 1, 2023 to September 30, 2024
MetricValue
Inventory$1.87 Billion
Liabilities$36.13 Billion
Current Assets$14.78 Billion
Equity Attributable To Noncontrolling Interest$-84.00 Million
Long-term Debt$23.25 Billion
Liabilities And Equity$54.52 Billion
Current Liabilities$11.72 Billion
Equity Attributable To Parent$18.48 Billion
Wages$1.05 Billion
Other Non-current Liabilities$1.16 Billion
Fixed Assets$5.39 Billion
Equity$18.39 Billion
Assets$54.52 Billion
Other Current Liabilities$9.77 Billion
Intangible Assets$20.55 Billion
Noncurrent Liabilities$24.41 Billion
Noncurrent Assets$39.75 Billion
Accounts Payable$903.00 Million
Other Non-current Assets$13.81 Billion
Other Current Assets$12.91 Billion

Historical Dividends

Current dividend: $0.77 Per Share Quarterly
Announcement DatePayment DateRecord DateAmountFrequency
Nov 6, 2024Dec 30, 2024Dec 13, 2024$0.77Quarterly
Aug 8, 2024Sep 27, 2024Sep 13, 2024$0.77Quarterly
Apr 25, 2024Jun 27, 2024Jun 14, 2024$0.77Quarterly
Feb 1, 2024Mar 28, 2024Mar 15, 2024$0.77Quarterly
Nov 7, 2023Dec 28, 2023Dec 15, 2023$0.75Quarterly
Aug 3, 2023Sep 28, 2023Sep 15, 2023$0.75Quarterly
Apr 27, 2023Jun 29, 2023Jun 15, 2023$0.75Quarterly
Feb 2, 2023Mar 30, 2023Mar 15, 2023$0.75Quarterly
Oct 27, 2022Dec 29, 2022Dec 15, 2022$0.73Quarterly
Aug 2, 2022Sep 29, 2022Sep 15, 2022$0.73Quarterly
Feb 1, 2022Mar 30, 2022Mar 15, 2022$0.73Quarterly
Oct 28, 2021Dec 30, 2021Dec 15, 2021$0.71Quarterly
Jul 29, 2021Sep 29, 2021Sep 15, 2021$0.71Quarterly
Apr 27, 2021Jun 29, 2021Jun 15, 2021$0.71Quarterly
Feb 4, 2021Mar 30, 2021Mar 15, 2021$0.71Quarterly
Oct 28, 2020Dec 30, 2020Dec 15, 2020$0.68Quarterly
Jul 30, 2020Sep 29, 2020Sep 15, 2020$0.68Quarterly
Apr 29, 2020Jun 29, 2020Jun 12, 2020$0.68Quarterly
Feb 3, 2020Mar 30, 2020Mar 13, 2020$0.68Quarterly
Oct 23, 2019Dec 30, 2019Dec 13, 2019$0.63Quarterly
Jul 29, 2019Sep 27, 2019Sep 13, 2019$0.63Quarterly
May 1, 2019Jun 27, 2019Jun 14, 2019$0.63Quarterly
Feb 1, 2019Mar 28, 2019Mar 15, 2019$0.63Quarterly
Oct 24, 2018Dec 28, 2018Dec 14, 2018$0.57Quarterly
Jul 24, 2018Sep 27, 2018Sep 14, 2018$0.57Quarterly
Apr 30, 2018Jun 28, 2018Jun 15, 2018$0.57Quarterly
Feb 5, 2018Mar 29, 2018Mar 16, 2018$0.57Quarterly
Oct 25, 2017Dec 28, 2017Dec 15, 2017$0.52Quarterly
Jul 25, 2017Sep 28, 2017Sep 15, 2017$0.52Quarterly
May 2, 2017Jun 29, 2017Jun 16, 2017$0.52Quarterly
Feb 6, 2017Mar 30, 2017Mar 16, 2017$0.52Quarterly
Nov 1, 2016Dec 29, 2016Dec 15, 2016$0.47Quarterly
Jul 22, 2016Sep 29, 2016Sep 16, 2016$0.47Quarterly
Apr 27, 2016Jun 29, 2016Jun 16, 2016$0.47Quarterly
Feb 2, 2016Mar 30, 2016Mar 16, 2016$0.43Quarterly
Oct 26, 2015Dec 30, 2015Dec 16, 2015$0.43Quarterly
Jul 23, 2015Sep 29, 2015Sep 16, 2015$0.43Quarterly
Apr 24, 2015Jun 29, 2015Jun 16, 2015$0.43Quarterly

Related Companies

View additional S&P 500 companies similar to Gilead Sciences Inc (GILD)
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
Earnings CalendarNews ArticlesAbout UsPrivacy & Cookies Info

ⓒ 2024 Financhle. All Rights Reserved.